Skip to main content

Table 3 Geometric means (68% inter-percentile range) of the main pharmacokinetic variables for formoterol at steady state

From: No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study

 

Regimen B

Regimen A

 

Day 8 (formoterol alone)

(n = 13)

Day 18 (formoterol plus roflumilast)

(n = 12)

Day 18 (roflumilast plus formoterol)

(n = 12)

Formoterol

   

Ctrough (μg/L)

4.12 (3.05-5.57)

3.94 (3.13-4.96)

4.23 (2.43-7.38)

Cmax (μg/L)

16.7 (11.5-24.3)

17.2 (12.3-24.1)

18.7 (14.3-24.6)

AUCτ (μg.h/L)

96.7 (72.8-128)

93.1 (72.7-119)

93.2 (72.9-119)

  1. AUCÏ„, area under the plasma concentration versus time curve; Cmax, maximum plasma concentration; Ctrough, trough plasma concentration.
Back to article page

BMC Clinical Pharmacology

ISSN: 1472-6904